SCHEMBL692996

SCHEMBL692996

CN(C(=O)O)c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
POLB P06746 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.46
LMNA P02545 1/20 0.46
CHRNB2 P17787 1/20 0.46
CHRNB4 P30926 1/20 0.46
CHRNA3 P32297 1/20 0.46
CHRNA4 P43681 1/20 0.46
MAPT P10636 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALOX15 P16050 3/20 0.44
TSHR P16473 2/20 0.44
RAB9A P51151 3/20 0.44
GPBAR1 Q8TDU6 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPC1 O15118 2/20 0.44
HTT P42858 1/20 0.44
HSD17B10 Q99714 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11842627 0.98 ALDH1A1 (0.47) ALDH1A1POLBTDP1L3MBTL1LMNA
SCHEMBL12550518 0.84 POLB (0.50) ALDH1A1POLBTDP1L3MBTL1LMNA
SCHEMBL11176346 0.84 ALDH1A1 (0.43) ALDH1A1POLBTDP1L3MBTL1LMNA
SCHEMBL28875183 0.83 ALDH1A1 (0.46) ALDH1A1POLBTDP1L3MBTL1LMNA
SCHEMBL198522 0.82 FSCN1 (0.55) ALDH1A1POLBTDP1LMNACHRNB2
SCHEMBL2095575 0.82 ALDH1A1 (0.48) ALDH1A1POLBTDP1L3MBTL1LMNA
SCHEMBL8986913 0.82 ALDH1A1 (0.48) ALDH1A1POLBTDP1L3MBTL1LMNA
SCHEMBL11788282 0.81 HDAC1 (0.44) ALDH1A1POLBMAPTSMN1; SMN2RAB9A
SCHEMBL10942532 0.80 ALDH1A1 (0.47) ALDH1A1POLBTDP1L3MBTL1LMNA
SCHEMBL18311982 0.80 ALDH1A1 (0.47) ALDH1A1POLBTDP1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406216-B1 HALOGENALKYLMETHYLENOXY-PHENYL-SUBSTITUTED KETOENOLS BAYER IP GMBH (DE) 2017-04-19 EP claimed
EP-4680598-A1 4-DIFLUOROMETHYL BENZAMIDES WITH HERBICIDAL ACTION Bayer Aktiengesellschaft (DE) 2026-01-21 EP disclosed
WO-2025224076-A1 SUBSTITUTED ARYLPYRAZINES AND SALTS THEREOF, AND USE THEREOF AS HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 2025-10-30 WO disclosed
EP-4602036-A1 SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES Bayer Aktiengesellschaft (DE) 2025-08-20 EP disclosed
WO-2025103927-A1 SUBSTITUTED OXYIMINOMETHYLPHENYL URACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 2025-05-22 WO disclosed
WO-2025103931-A1 SUBSTITUTED CYCLOPROPYLOXYPHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 2025-05-22 WO disclosed
WO-2025103929-A1 SUBSTITUTED N-BENZOIC ACID URACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 2025-05-22 WO disclosed
EP-4440314-A1 (1,4,5-TRISUBSTITUTED-1H-PYRAZOLE-3-YL)OXY-2-ALKOXYTHIO ALKYL ACIDS AND DERIVATIVES THEREOF, THEIR SALTS AND THEIR USE AS HERBICIDAL ACTIVE AGENTS Bayer Aktiengesellschaft (DE) 2024-10-09 EP disclosed
WO-2024194026-A1 4-DIFLUOROMETHYL BENZAMIDES WITH HERBICIDAL ACTION BAYER AKTIENGESELLSCHAFT (DE) 2024-09-26 WO disclosed
WO-2024104952-A1 SUBSTITUTED CYCLOPROPYLOXYPHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES BAYER AKTIENGESELLSCHAFT (DE) 2024-05-23 WO disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed
EP-0161550-B1 PROCESS FOR PRODUCING AN ALIPHATIC ISOCYANATE Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1988-01-20 EP disclosed
US-4587056-A CARBONYLATION, OXIDATION, CATALYST ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1986-05-06 US disclosed
EP-0161550-A1 Process for producing an aliphatic isocyanate Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1985-11-21 EP disclosed
US-4537622-A POSTEMERGENECE HERBICIDES SCHERING AKTIENGESELLSCHAFT (DE) 1985-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ALDH1A1 412/4885POLB 757/4885TDP1 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.